Literature DB >> 21084754

Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs.

Noelia Rivera1, Christopher J Ramnanan, Zhibo An, Tiffany Farmer, Marta Smith, Ben Farmer, Jose M Irimia, Wanda Snead, Margaret Lautz, Peter J Roach, Alan D Cherrington.   

Abstract

In individuals with type 1 diabetes, hypoglycemia is a common consequence of overinsulinization. Under conditions of insulin-induced hypoglycemia, glucagon is the most important stimulus for hepatic glucose production. In contrast, during euglycemia, insulin potently inhibits glucagon's effect on the liver. The first aim of the present study was to determine whether low blood sugar augments glucagon's ability to increase glucose production. Using a conscious catheterized dog model, we found that hypoglycemia increased glucagon's ability to overcome the inhibitory effect of insulin on hepatic glucose production by almost 3-fold, an effect exclusively attributable to marked enhancement of the effect of glucagon on net glycogen breakdown. To investigate the molecular mechanism by which this effect comes about, we analyzed hepatic biopsies from the same animals, and found that hypoglycemia resulted in a decrease in insulin signaling. Furthermore, hypoglycemia and glucagon had an additive effect on the activation of AMPK, which was associated with altered activity of the enzymes of glycogen metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084754      PMCID: PMC2993579          DOI: 10.1172/JCI40919

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism.

Authors:  D S Edgerton; S Cardin; M Emshwiller; D Neal; V Chandramouli; W C Schumann; B R Landau; L Rossetti; A D Cherrington
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

2.  Glucose-6-phosphate dehydrogenase regulation during hypometabolism.

Authors:  Christopher J Ramnanan; Kenneth B Storey
Journal:  Biochem Biophys Res Commun       Date:  2005-10-18       Impact factor: 3.575

3.  Control of liver glycogen synthase activity and intracellular distribution by phosphorylation.

Authors:  Susana Ros; Mar García-Rocha; Jorge Domínguez; Juan C Ferrer; Joan J Guinovart
Journal:  J Biol Chem       Date:  2009-01-05       Impact factor: 5.157

4.  5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin.

Authors:  Raul C Camacho; D Brooks Lacy; Freyja D James; E Patrick Donahue; David H Wasserman
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-07-26       Impact factor: 4.310

5.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism.

Authors:  Seung-Hoi Koo; Lawrence Flechner; Ling Qi; Xinmin Zhang; Robert A Screaton; Shawn Jeffries; Susan Hedrick; Wu Xu; Fayçal Boussouar; Paul Brindle; Hiroshi Takemori; Marc Montminy
Journal:  Nature       Date:  2005-09-07       Impact factor: 49.962

6.  Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP.

Authors:  Rebecca L Hurley; Laura K Barré; Sumintra D Wood; Kristin A Anderson; Bruce E Kemp; Anthony R Means; Lee A Witters
Journal:  J Biol Chem       Date:  2006-10-05       Impact factor: 5.157

7.  Hepatic energy state is regulated by glucagon receptor signaling in mice.

Authors:  Eric D Berglund; Robert S Lee-Young; Daniel G Lustig; Sara E Lynes; E Patrick Donahue; Raul C Camacho; M Elizabeth Meredith; Mark A Magnuson; Maureen J Charron; David H Wasserman
Journal:  J Clin Invest       Date:  2009-08       Impact factor: 14.808

8.  A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog.

Authors:  Noelia Rivera; Carrie A Everett-Grueter; Dale S Edgerton; Tiffany Rodewald; Doss W Neal; Erica Nishimura; Marianne O Larsen; Lene O Jacobsen; Kim Kristensen; Christian L Brand; Alan D Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2007-02-16       Impact factor: 4.030

9.  AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex.

Authors:  Santiago Vernia; M Carmen Solaz-Fuster; José Vicente Gimeno-Alcañiz; Teresa Rubio; Luisa García-Haro; Marc Foretz; Santiago Rodríguez de Córdoba; Pascual Sanz
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

Review 10.  Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes.

Authors:  G J Taborsky; B Ahrén; P J Havel
Journal:  Diabetes       Date:  1998-07       Impact factor: 9.461

View more
  21 in total

1.  Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes.

Authors:  A Maharaj; L Zhu; F Huang; H Qiu; H Li; C Y Zhang; T Jin; Q Wang
Journal:  Diabetologia       Date:  2012-02-09       Impact factor: 10.122

2.  Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis.

Authors:  Jason J Winnick; Guillaume Kraft; Justin M Gregory; Dale S Edgerton; Phillip Williams; Ian A Hajizadeh; Maahum Z Kamal; Marta Smith; Ben Farmer; Melanie Scott; Doss Neal; E Patrick Donahue; Eric Allen; Alan D Cherrington
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

3.  Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects.

Authors:  Jessica R Castle; Joseph El Youssef; Deborah Branigan; Brett Newswanger; Poul Strange; Martin Cummins; Leon Shi; Steven Prestrelski
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

Review 4.  Physiologic action of glucagon on liver glucose metabolism.

Authors:  C J Ramnanan; D S Edgerton; G Kraft; A D Cherrington
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

Review 5.  Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.

Authors:  W Kenneth Ward; Jessica R Castle; Joseph El Youssef
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

6.  Glucose autoregulation is the dominant component of the hormone-independent counterregulatory response to hypoglycemia in the conscious dog.

Authors:  Justin M Gregory; Noelia Rivera; Guillaume Kraft; Jason J Winnick; Ben Farmer; Eric J Allen; E Patrick Donahue; Marta S Smith; Dale S Edgerton; Phillip E Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-16       Impact factor: 4.310

7.  Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Authors:  Ling Hinshaw; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Claudio Cobelli; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-07       Impact factor: 4.310

8.  Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trials.

Authors:  Yan Zheng; Uta Ceglarek; Tao Huang; Lerong Li; Jennifer Rood; Donna H Ryan; George A Bray; Frank M Sacks; Dan Schwarzfuchs; Joachim Thiery; Iris Shai; Lu Qi
Journal:  Am J Clin Nutr       Date:  2016-01-20       Impact factor: 7.045

9.  A novel antihypoglycemic role of inducible nitric oxide synthase in liver inflammatory response induced by dietary cholesterol and endotoxemia.

Authors:  Sarit Anavi; Michal Hahn-Obercyger; Raanan Margalit; Zecharia Madar; Oren Tirosh
Journal:  Antioxid Redox Signal       Date:  2013-07-24       Impact factor: 8.401

10.  The kinetics of glucagon action on the liver during insulin-induced hypoglycemia.

Authors:  Christina Pedersen; Guillaume Kraft; Dale S Edgerton; Melanie Scott; Ben Farmer; Marta Smith; David C Laneve; Phillip E Williams; L Merkle Moore; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-03-24       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.